Two immunochemical assays to measure advanced glycation end-products in serum from dialysis patients

References

1 Papanastasiou P, Grass L, Rodela H, Patrikarea A, Oreopoulos D, Diamandis E. Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney Int 1994; 46: 216–22. 10.1038/ki.1994.262Search in Google Scholar

2 Ateshkadi A, Johnson C, Founds H, Zimmerman S. Serum advanced glycosylation end-products in patients on hemodialysis and CAPD. Perit Dial Int 1995; 15: 129–33. 10.1177/089686089501500207Search in Google Scholar

3 Takayama F, Aoyama I, Tsukushi S, Miyazaki T, Miyazaki S, Morita T, et al. Immunohistochemical detection of imidazolone and N ε-(carboxymethyl)lysine in aortas of hemodialysis patients. Cell Mol Biol 1997; 44: 1101–9. Search in Google Scholar

4 Dawnay A, Millar D. The pathogenesis and consequences of AGE formation in uraemia and its treatment. Cell Mol Biol 1997; 44: 1081–94. Search in Google Scholar

5 Friedlander M, Wu Y, Elgawish A, Monnier V. Early and advanced glycosylation end products. Kinetics of formation and clearance in peritoneal dialysis. J Clin Invest 1996; 97: 728–35. 10.1172/JCI118471Search in Google Scholar

6 Miyata T, Ueda Y, Saito A, Kurokawa K. Carbonyl stress and dialysis-related amyloidosis. Nephrol Dial Transplant 2000; 15(Suppl 1): 25–8. 10.1093/oxfordjournals.ndt.a027959Search in Google Scholar

7 Miyata T, Fu M, Kurokawa K, van Ypersele de Strihou C, Thorpe S, Baynes J. Autoxidation product of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia? Kidney Int 1998; 54: 1290–5. 10.1046/j.1523-1755.1998.00093.xSearch in Google Scholar

8 Makita Z, Bucala R, Rayfield E, Friedman E, Kaufman A, Korbet S, et al. Reactive glycosylation endproducts in diabetic uremia and treatment of renal failure. Lancet 1994; 343: 1519–22. 10.1016/S0140-6736(94)92935-1Search in Google Scholar

9 Yanagisawa K, Makita Z, Shiroshita K, Ueda T, Fusegawa T, Kuwajima S, et al. Specific fluorescence assay for advanced glycation end products in blood and urine of diabetic patients. Metabolism 1998; 47: 1348–53. 10.1016/S0026-0495(98)90303-1Search in Google Scholar

10 Makita Z, Radoff S, Rayfield E, Yang Z, Skolnik E, Delaney V, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325: 836–42. 10.1056/NEJM199109193251202Search in Google Scholar PubMed

11 Tsukushi S, Katsuzako T, Aoyama I, Takayama F, Mityazaki T, Shimokata K, et al. Increased erythrocyte 3-DG and AGEs in diabetic hemodialysis patients: role of the polyol pathway. Kidney Int 1999; 55: 1970–6. 10.1046/j.1523-1755.1999.00418.xSearch in Google Scholar PubMed

12 Miyata T, Ueda Y, Yamada Y, Izuhara Y, Wada T, Jadoul M, et al. Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: carbonyl stress in uremia. J Am Soc Nephrol 1998; 9: 2349–56. 10.1681/ASN.V9122349Search in Google Scholar PubMed

13 Miyata T, Wada Y, Cai Z, Iida Y, Horie K, Yasuda Y, et al. Implications of an increased oxidative stress in the formation of advanced glycation endproducts in patients with end-stage renal failure. Kidney Int 1997; 51: 1170–81. 10.1038/ki.1997.160Search in Google Scholar

14 Münch G, Keis R, Wessels A, Riederer P, Bahner U, Heidland A, et al. Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem 1997; 35: 669–77. 10.1515/cclm.1997.35.9.669Search in Google Scholar

15 Dolhofer-Bliesener R, Lechner B, Deppisch R, Ritz E, Gerbitz K. Immunological determination of advanced glycosylation end-products in human blood and urine. Nephrol Dial Transplant 1995; 10: 657–64. Search in Google Scholar

16 Odetti P, Cosso L, Pronzato M, Dapino D, Gurreri G. Plasma advanced glycosylation end-products in maintenance haemodialysis patients. Nephrol Dial Transplant 1995; 10: 2110–3. Search in Google Scholar

17 Friedlander M, Wu Y, Schulak J, Monnier V, Hricik D. Influence of dialysis modality on plasma and tissue concentrations of pentosidine in patients with end-stage renal disease. Am J Kidney Dis 1995; 25: 445–51. 10.1016/0272-6386(95)90107-8Search in Google Scholar

18 Kaysen G. The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol 2001; 12: 1549–57. 10.1681/ASN.V1271549Search in Google Scholar PubMed

19 Aso Y, Inukai K, Takemura Y. Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes. Acta Diabetol 2000; 37: 87–92. 10.1007/s005920070025Search in Google Scholar PubMed

20 Pischetsrieder M. Chemistry of glucose and biochemical pathways of biological interest. Perit Dial Int 2000; 20: 26–30. 10.1177/089686080002002S06Search in Google Scholar

21 Degenhardt T, Grass L, Reddy S, Thorpe S, Diamandis E, Baynes J. The serum concentration of the advanced glycation end-product N ε-(carboxymethyl)lysine is increased in uremia. Kidney Int 1997; 52: 1064–7. 10.1038/ki.1997.429Search in Google Scholar PubMed

22 Sell D, Monnier V. End-stage renal disease and diabetes catalyze the formation of a pentose-derived cross-link from aging human collagen. J Clin Invest 1990; 85: 380–4. 10.1172/JCI114449Search in Google Scholar PubMed PubMed Central

23 Stein G, Franke S, Mahiout A, Schneider S, Sperschneider H, Borst S, et al. Influence of dialysis modalities on serum AGE levels in end-stage renal disease patients. Nephrol Dial Transplant 2001; 16: 999–1008. 10.1093/ndt/16.5.999Search in Google Scholar PubMed

24 Satoh M, Yamasaki Y, Nagake Y, Kasahara J, Hashimoto M, Nakanishi N, et al. Oxidative stress is reduced by the long-term use of vitamin E-coated dialysis filters. Kidney Int 2001; 59: 1943–50. 10.1046/j.1523-1755.2001.0590051943.xSearch in Google Scholar PubMed

25 Niwa T, Katsuzaki T, Miyazaki S, Miyazaki T, Ishizaki Y, Hayase F, et al. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J Clin Invest 1997; 99: 1272–80. 10.1172/JCI119285Search in Google Scholar

26 Mellinghoff A, Reininger A, Wuerth J, Founds H, Landgraf R, Hepp K. Formation of plasma advanced glycosylation end products (AGEs) has no influence on plasma viscosity. Diabet Med 1997; 14: 832–6. 10.1002/(SICI)1096-9136(199710)14:10<832::AID-DIA492>3.0.CO;2-9Search in Google Scholar

27 Galler A, Muller G, Schinzel R, Kratzsch J, Kiess W, Munch G. Impact of metabolic control and serum liquids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and n epsilon-(carboxymethyl)lysine ELISA. Diabetes Care 2003; 26: 2609–15. 10.2337/diacare.26.9.2609Search in Google Scholar

28 Sebekova K, Krajcovicova-Kudlackova M, Schinzel R, Faist V, Klvanova J, Heidland A. Plasma levels of advanced glycation end products in healthy, long-term vegetarians and subjects on a western mixed diet. Eur J Nutr 2001; 40: 275–81. 10.1007/s394-001-8356-3Search in Google Scholar

29 Sebekova K, Kupcova V, Schinzel R, Heidland A. Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis – amelioration by liver transplantation. J Hepatol 2002; 36: 66–71. 10.1016/S0168-8278(01)00232-XSearch in Google Scholar

30 Gerdemann A, Lemke HD, Nothdurft A, Heidland A, Munch G, Bahner U, Schinzel R. Low-molecular but not high-molecular advanced glycation end products (AGEs) are removed by high-flux dialysis. Clin Nephrol 2000; 54: 276–83. Search in Google Scholar

31 Niwa T, Katsuzaki T, Miyazaki S, Momoi T, Akiba T, Miyazaki T, et al. Amyloid beta 2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis. Kidney Int 1997; 51: 187–94. 10.1038/ki.1997.23Search in Google Scholar

32 Huber B, Pischetsrieder M. Characterization of ascorbylated proteins by immunochemical methods. J Agric Food Chem 1998; 46: 3985–90. 10.1021/jf9803132Search in Google Scholar

33 Fields R. The rapid determination of amino groups with TNBS. Methods Enzymol 1972; 15: 464–8. 10.1016/S0076-6879(72)25042-XSearch in Google Scholar

34 Madson M, Feather M. An improved preparation of 3-deoxy-D-erythro-hexos-2-ulose via the bis(benozoyl-hydrazone) and some related constitutional studies. Carbohydr Res 1981; 94: 183–91. 10.1016/S0008-6215(00)80716-8Search in Google Scholar

35 Humeny A, Kislinger T, Becker CM, Pischetsrieder M. Qualitative determination of specific protein glycation products by matrix-assisted laser desorption/ionization mass spectrometry peptide mapping. J Agric Food Chem 2002; 50: 2153–60. 10.1021/jf011349oSearch in Google Scholar

36 Reddy S, Bichler J, Wells-Knecht K, Thorpe S, Baynes J. N ε-(Carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 1995; 34: 10872–8. 10.1021/bi00034a021Search in Google Scholar PubMed

37 Pischetsrieder M, Larisch B, Seidel W. Immunochemical detection of oxalic acid monoamides which are formed during the oxidative reaction of L-ascorbic acid and proteins. J Agric Food Chem 1997; 45: 2070–5. 10.1021/jf960919vSearch in Google Scholar

38 Kalusouva M, Sulkova S, Fialova L, Soukupova J, Malbohan I, Spacek P, et al. Glycoxidation and inflammation in chronic haemodialysis patients. Nephrol Dial Transplant 2003; 18: 2577–81. 10.1093/ndt/gfg404Search in Google Scholar PubMed

39 Izuhara Y, Miyata T, Ueda Y, Suzuki D, Asahi K, Inagi R, et al. A sensitive and specific ELISA for plasma pentosidine. Nephrol Dial Transplant 1999; 14: 576–80. 10.1093/ndt/14.3.576Search in Google Scholar PubMed

40 Henle T, Deppisch R, Beck W, Hergesell O, Hansch G, Ritz E. Advanced glycation end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. Nephrol Dial Transplant 1999; 14: 1968–75. 10.1093/ndt/14.8.1968Search in Google Scholar PubMed

41 Williams J, Topley N, Craig K, Mackenzie R, Pischetsrieder M, Lage C, et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66: 408–18. 10.1111/j.1523-1755.2004.00747.xSearch in Google Scholar PubMed

42 Schmidt A, Hori O, Chen J, Li J, Crandall J, Zhang J, et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. J Clin Invest 1995; 96: 1395–403. 10.1172/JCI118175Search in Google Scholar PubMed PubMed Central

43 Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Yan S, et al. N ε-(Carboxymethyl)lysine adducts of proteins are ligands for RAGE (receptor for AGE) that activate cell signalling pathways and modulate gene expression. J Biol Chem 1999; 274: 31740–9. 10.1074/jbc.274.44.31740Search in Google Scholar PubMed

44 Kislinger T, Tanji N, Qu W, Lu Y, Ferran L, Taguchi A, et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E null mice. Arterioscler Thromb Vasc Biol 2001; 21: 905–10. 10.1161/01.ATV.21.6.905Search in Google Scholar

45 Park L, Raman K, Lee K, Lu Y, Ferran L, Chow W, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998; 4: 1025–31. 10.1038/2012Search in Google Scholar PubMed

46 Zimmeck T, Tauer A, Fuenfrocken M, Pischetsrieder M. How to reduce 3-deoxyglucosone and acetaldehyde in peritoneal dialysis fluids. Perit Dial Int 2002; 22: 350–6. 10.1177/089686080202200309Search in Google Scholar

47 Tauer A, Knerr T, Niwa T, Schaub T, Lage C, Passlick-Deetjen J, et al. In vitro formation of N ε-(carboxymethyl)lysine and imidazolones under conditions similar to continuous ambulatory peritoneal dialysis. Biochem Biophys Res Commun 2001; 280: 1408–14. 10.1006/bbrc.2001.4294Search in Google Scholar PubMed

48 Linden T, Musi B, Järkelid L, Forsbäck G, Kjellstrand P, Deppisch R, et al. Glucose degradation products in peritoneal dialysis fluids may have both local and systemic effects: a study of residual fluid and mesothelial cells. Perit Dial Int 2001; 21: 607–24. 10.1177/089686080102100612Search in Google Scholar

49 Zhang X, Niwa T, Bosselmann P, Domröse U, Kuhlmann U, Mettang T, et al. Serum imidazolone in CAPD patients treated three months with standard PD fluid (PDF) and three months with the new dual-chambered PDF Balance. Perit Dial Int 2002; 22(Suppl 1): 18. Search in Google Scholar